Novartis Portugal

What Novartis Portugal does

Novartis Portugal is the Portuguese operating affiliate of Novartis AG, the Swiss-headquartered multinational pharmaceutical company. The affiliate commercializes innovative prescription medicines across four therapeutic areas — cardiovascular/renal/metabolic diseases, immunology, neuroscience, and oncology — and has extended into advanced therapy medicinal products, including Zolgensma gene therapy for spinal muscular atrophy following INFARMED approval and reimbursement in Portugal.

The subsidiary distributes and markets its medicines to Portuguese healthcare professionals and institutions through a field sales motion that targets hospitals, specialist prescribers, and primary-care networks, with patient reach enabled via both the public National Health Service (Serviço Nacional de Saúde) and private hospital providers. Beyond product commercialization, Novartis Portugal operates clinical trial activity in country across its four therapeutic areas, with trial volume having grown 52% over a four-year window, signaling an evolving dual role as a commercial affiliate and an in-country R&D site within the Novartis global development network.

The affiliate has invested in digital and content channels, including MedHub PT, a healthcare-professional-facing platform for medical and scientific content, and the Novartis PodeCast, an audio channel aimed at HCPs and broader audiences. Together these support engagement beyond the field sales force. The organization is headquartered in the greater Lisbon area (Porto Salvo), carries Top Employer 2021 certification, and operates as a country-level subsidiary within the parent Novartis global footprint, which reaches approximately 296 million patients and touches 766 million lives worldwide.

Name

Novartis Portugal

Legal name

Novartis Portugal

Website

https://novartis.pt

Company type

Public

Operating status

Operating

Short description

Novartis Portugal is the Portuguese operating affiliate of Swiss multinational Novartis AG, commercializing innovative prescription medicines across cardiovascular, immunology, neuroscience, and oncology therapeutic areas — including gene therapy — to patients, HCPs, and hospitals via field sales and digital channels.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Prescription pharmaceuticals
• Innovative medicines
• Gene therapy
• Clinical research
• Oncology treatments

Headquarters

HQ city

Porto Salvo

HQ country

Portugal

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical Medicines Sales: Novartis generates revenue through the sale of prescription medicines to healthcare systems, hospitals, pharmacies, and healthcare professionals. Products are distributed through traditional pharmaceutical supply chains to patients via healthcare providers.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Novartis Portugal develops, manufactures, and distributes prescription pharmaceutical medicines across four therapeutic areas: cardiovascular, renal and metabolic; immunology; neuroscience; and oncology. The portfolio includes innovative medicines, small molecule drugs, and gene therapies (such as Zolgensma approved by INFARMED for spinal muscular atrophy). Supporting offerings include the MedHub PT digital platform for healthcare professionals and clinical trial programs in Portugal.

Product overview

Novartis Portugal operates as the Portuguese subsidiary of Novartis AG, an innovative medicines company. The company offers a portfolio of pharmaceutical products across four main therapeutic areas: Cardiovascular, renal and metabolic diseases; Immunology; Neuroscience; and Oncology. Supporting its core pharmaceutical business, Novartis Portugal provides digital platforms including MedHub PT for healthcare professionals and the Novartis PodeCast digital content series. The company also maintains clinical trial programs, ESG initiatives, and various patient and healthcare professional support resources. The product portfolio includes the global Novartis Pipeline of investigational medicines and the established Products portfolio available in Portugal.

Differentiator

Problem solved

Functional benefit

Products and services

• Prescription Pharmaceutical Portfolio

Quantifiable outcome

• 766 million lives touched by Novartis products globally
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• MedHub PTcoreTechnology or IntegrationMedHub PT is a dedicated digital platform for healthcare professionals in Portugal, providing access to medical information, professional resources, and tools to support patient care and continuing medical education.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Roche Portugal: Portuguese subsidiary of Roche Holding, one of the world's largest innovative pharmaceutical companies. Roche Portugal competes head-to-head with Novartis Portugal across oncology, immunology, and neuroscience, with similar HCP-facing field sales models and NHS-driven reimbursement dynamics in Portugal.
• Pfizer Portugal: Local entity of Pfizer Inc., a top-tier global pharmaceutical company with a broad innovative-medicines portfolio. Pfizer Portugal overlaps with Novartis Portugal across multiple therapeutic categories and competes for the same HCP relationships, NHS reimbursement slots, and clinical trial sites in Portugal.
• Sanofi Portugal: Portuguese affiliate of Sanofi S.A., a global innovative pharma with strong immunology, vaccines, and specialty care portfolios. Sanofi Portugal is directly comparable in business model (branded innovative medicines, NHS reimbursement, HCP field sales) and overlapping therapeutic areas with Novartis Portugal.
• MSD (Merck) Portugal: Portuguese operation of Merck & Co. (MSD), a leading global pharmaceutical company with major oncology and vaccine franchises. MSD Portugal competes in similar therapeutic areas, follows the same NHS reimbursement model, and targets the same prescriber base as Novartis Portugal.
• AstraZeneca Portugal: Portuguese subsidiary of AstraZeneca plc, with strong oncology, cardiovascular, and respiratory portfolios. Directly comparable to Novartis Portugal in operating model, therapeutic overlap (notably cardiovascular and oncology), and regulatory/reimbursement pathway.
• GSK Portugal: Portuguese affiliate of GSK plc, a global pharmaceutical company with vaccines, specialty medicines, and general medicines. GSK Portugal is comparable in scale, HCP-targeting model, and NHS-driven pricing environment, with some therapeutic overlap in immunology and respiratory.
• Bayer Portugal: Portuguese subsidiary of Bayer AG's pharmaceutical division, with franchises in cardiology, women's health, and oncology. Bayer Portugal overlaps with Novartis Portugal's cardiovascular/metabolic franchise and shares the same NHS reimbursement and field-sales GTM motion.
• Johnson & Johnson Innovative Medicine Portugal: Portuguese affiliate of J&J's Innovative Medicine division, focused on oncology, immunology, and neuroscience. Directly comparable to Novartis Portugal in therapeutic focus, HCP engagement model, and NHS pricing dynamics.
• AbbVie Portugal: Portuguese subsidiary of AbbVie Inc., a major pharmaceutical company with leading immunology, neuroscience, and oncology franchises. AbbVie Portugal is a closely comparable specialty pharma operator in Portugal with substantial overlap in immunology and neuroscience.
• Bristol-Myers Squibb Portugal: Portuguese affiliate of Bristol-Myers Squibb, a global biopharma with major oncology, immunology, and cardiovascular franchises. BMS Portugal competes with Novartis Portugal for the same specialist prescribers and NHS budget, with a similar specialty-pharma operating model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/novartis-portugal

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novartis Portugal